Ishii Seigo, Tamiya Akihiro, Taniguchi Yoshihiko, Tanaka Tsunehiro, Abe Yuko, Isa Shun-Ichi, Tsuyuguchi Kazunari, Suzuki Katsuhiro, Atagi Shinji
Department of Internal Medicine, Kinki-chuo Chest Medical Center, Japan.
Department of Thoracic Oncology, Kinki-chuo Chest Medical Center, Japan.
Intern Med. 2018 Dec 15;57(24):3625-3629. doi: 10.2169/internalmedicine.1195-18. Epub 2018 Aug 10.
Nivolumab has become the standard second-line chemotherapy for non-small cell lung cancer. A 73-year-old man with stage IV non-small cell lung cancer received 6 cycles of chemotherapy with nab-paclitaxel/carboplatin/bevacizumab followed by 11 cycles of nab-paclitaxel/bevacizumab; however, treatment was stopped due to pneumothorax. One year after therapy started, a nodule appeared in the left upper lung and increased in size. Mycobacterium abscessus subsp. massiliense disease was diagnosed by a sputum analysis. After short antibiotic treatment, nivolumab was administered. Two months after nivolumab treatment, the nodule improved along with a good tumour response. The effectiveness of nivolumab for chronic infectious diseases, such as M. abscessus disease, should be investigated.
纳武单抗已成为非小细胞肺癌的标准二线化疗药物。一名73岁的IV期非小细胞肺癌男性患者接受了6个周期的白蛋白结合型紫杉醇/卡铂/贝伐单抗化疗，随后接受了11个周期的白蛋白结合型紫杉醇/贝伐单抗化疗；然而，由于气胸，治疗停止。治疗开始一年后，左肺上叶出现一个结节，且大小增大。通过痰液分析诊断为脓肿分枝杆菌马西利亚亚种病。经过短期抗生素治疗后，给予纳武单抗。纳武单抗治疗两个月后，结节改善，肿瘤反应良好。应研究纳武单抗对慢性传染病如脓肿分枝杆菌病的有效性。
